polycystic%20ovarian%20syndrome
POLYCYSTIC OVARIAN SYNDROME
Polycystic ovarian syndrome (PCOS) is the accumulation of underdeveloped follicles in the ovaries due to anovulation. It is is characterized by menstrual abnormalities and clinical or biochemical features of hyperandrogenism.
It results mainly from abnormal steroidogenesis that may be caused by insulin resistance leading to hyperinsulinemia.
There is increased sensitivity to androgens and the majority of women have elevated androgen levels.

Polycystic Ovarian Syndrome Drug Information

Drug Information

Indication: Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to die...

Indication: Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to die...

Indication: Monotherapy or in combination w/ other oral antidiabetics or insulin in type 2 DM inadequately controlled by d...

Indication: NIDDM when hyperglycemia cannot be controlled by diet management, exercise or wt reduction. Monotherapy or adj...

Indication: RA, acute gouty arthritis, bronchial asthma, serum sickness, lupus, nodular arthritis, allergic dermatitis, pe...

Indication: Type 2 DM inadequately controlled on metformin alone or who are already treated w/ combination of vildagliptin...

Indication: Women of reproductive age w/ moderate to severe acne related to androgen-sensitivity (w/ or w/o seborrhea) &am...

Indication: Type 2 DM when not adequately controlled by dietary management & exercise alone. Monotherapy or in combina...

1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 3 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.